Humanized antibodies that sequester amyloid beta peptide
First Claim
Patent Images
1. A method to inhibit the formation of amyloid plaques or to inhibit the formation of toxic soluble Aβ
- species in humans, comprising administering to a human subject in need of such inhibition an effective amount of a humanized antibody, wherein said antibody comprises;
a. a light chain comprising a light chain variable region comprising the following sequence;
9 Assignments
0 Petitions
Accused Products
Abstract
A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble Aβ peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide Aβ.
-
Citations
24 Claims
-
1. A method to inhibit the formation of amyloid plaques or to inhibit the formation of toxic soluble Aβ
- species in humans, comprising administering to a human subject in need of such inhibition an effective amount of a humanized antibody, wherein said antibody comprises;
a. a light chain comprising a light chain variable region comprising the following sequence; - View Dependent Claims (2, 3)
- species in humans, comprising administering to a human subject in need of such inhibition an effective amount of a humanized antibody, wherein said antibody comprises;
-
4. A method to reduce the formation of amyloid plaques or to reduce the formation of toxic soluble Aβ
- species in a human, comprising administering to a human subject in need of such reduction an effective amount of a humanized antibody, wherein said antibody comprises;
a. a light chain comprising a light chain variable region comprising the following sequence; - View Dependent Claims (5, 6)
- species in a human, comprising administering to a human subject in need of such reduction an effective amount of a humanized antibody, wherein said antibody comprises;
-
7. A method of treating, preventing, or reversing cognitive decline in a subject having clinical or pre-clinical Alzheimer'"'"'s disease, Down'"'"'s syndrome, or clinical or pre-clinical cerebral amyloid angiopathy, comprising administering to the subject an effective amount of a humanized antibody, wherein said antibody comprises:
a. a light chain comprising a light chain variable region comprising the following sequence; - View Dependent Claims (8, 9)
-
10. A method of treating, preventing, or reversing cognitive decline in a human subject having clinical or pre-clinical Alzheimer'"'"'s disease, Down'"'"'s syndrome, or clinical or pre-clinical cerebral amyloid angiopathy, comprising expressing recombinant sequences of a humanized antibody in human tissue, wherein said antibody comprises:
a. a light chain comprising a light chain variable region comprising the following sequence; - View Dependent Claims (11, 12)
-
13. A method of improving cognition in a human subject having clinical or pre-clinical Alzheimer'"'"'s disease, Down'"'"'s syndrome, or clinical or pre-clinical cerebral amyloid angiopathy, comprising administering to the subject an effective amount of a humanized antibody, wherein said antibody comprises:
a. a light chain comprising a light chain variable region comprising the following sequence; - View Dependent Claims (14, 15)
-
16. A method of therapeutically treating Alzheimer'"'"'s disease, comprising administering to a patient in need thereof an effective amount of a humanized antibody, wherein said antibody comprises:
a. a light chain comprising a light chain variable region comprising the following sequence; - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24)
Specification